European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...

Application based on results from the CheckMate -8HW study, in which Opdivo plus Yervoy demonstrated statistically significant and clinically meaningful improvement in progression-free survival...

Related Keywords

Japan ,Taiwan ,United States ,China ,South Korea ,American ,Yervoy Opdivo ,Bristol Myers Squibb ,Dana Walker ,American Society Of Clinical Oncology ,Youtube ,Linkedin ,Company Opdivo ,Exchange Commission ,Facebook ,Drug Administration ,Ono Pharmaceutical Co ,Twitter ,European Union ,Instagram ,European Medicines Agency ,Plus Yervoy ,First Line Treatment ,Adult Patients ,Microsatellite Instability ,Mismatch Repair Deficient Metastatic Colorectal ,Myers Squibb ,Bristol Myers ,Blinded Independent Clinical Review ,Clinical Oncology ,Gastrointestinal Cancers ,Better Future ,Fatal Immune Mediated Adverse Reactions ,Full Prescribing Information ,Allogeneic Hematopoietic Stem Cell ,Multiple Myeloma ,Thalidomide Analogue ,Prescribing Information ,Ono Pharmaceutical ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Markets ,